{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696758",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696758_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">Acenocoumarol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acenocoumarol   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696759",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696759_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"aciclovir\" outputclass=\"int-drug\">aciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  aciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696760",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696760_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"adefovir\" outputclass=\"int-drug\">adefovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  adefovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Adefovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696761",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696761_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal irritation when given with</ph> <ph otherprops=\"alendronic acid\" outputclass=\"int-drug\">alendronic acid</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   is predicted to   increase   the risk of gastrointestinal irritation when given with   alendronic acid .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alendronic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696762",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696762_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  aliskiren  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696763",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696763_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alteplase\" outputclass=\"int-drug\">Alteplase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alteplase   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696764",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696764_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"amikacin\" outputclass=\"int-drug\">amikacin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  amikacin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amikacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696765",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696765_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  amiloride  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696765_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  amiloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696766",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696766_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  amitriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696767",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696767_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"amphotericin\" outputclass=\"int-drug\">amphotericin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  amphotericin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696768",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696768_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  anagrelide  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696769",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696769_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apixaban\" outputclass=\"int-drug\">Apixaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apixaban   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696770",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696770_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"argatroban\" outputclass=\"int-drug\">Argatroban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Argatroban   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Argatroban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696771",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696771_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  aspirin  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696772",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696772_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">azilsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  azilsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696773",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696773_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"bacitracin\" outputclass=\"int-drug\">bacitracin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  bacitracin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacitracin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696774",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696774_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">beclometasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   beclometasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696775",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696775_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  bendroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696775_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Celecoxib   increases   the risk of acute renal failure when given with   bendroflumethiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696776",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696776_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">betamethasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   betamethasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696777",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696777_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  bevacizumab  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696778",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696778_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bivalirudin\" outputclass=\"int-drug\">Bivalirudin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bivalirudin   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bivalirudin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696779",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696779_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"budesonide\" outputclass=\"int-drug\">budesonide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   budesonide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696780",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696780_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  bumetanide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696781",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696781_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"candesartan\" outputclass=\"int-drug\">candesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  candesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696782",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696782_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cangrelor\" outputclass=\"int-drug\">cangrelor</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cangrelor  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cangrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696783",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696783_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"capreomycin\" outputclass=\"int-drug\">capreomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  capreomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capreomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696784",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696784_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  captopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696785",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696785_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">carbamazepine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  carbamazepine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696786",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696786_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  carboplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696787",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696787_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cefaclor\" outputclass=\"int-drug\">cefaclor</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cefaclor  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefaclor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696788",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696788_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cefadroxil\" outputclass=\"int-drug\">cefadroxil</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cefadroxil  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefadroxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696789",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696789_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cefalexin\" outputclass=\"int-drug\">cefalexin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cefalexin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefalexin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696790",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696790_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cefixime\" outputclass=\"int-drug\">cefixime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cefixime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefixime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696791",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696791_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cefotaxime\" outputclass=\"int-drug\">cefotaxime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cefotaxime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefotaxime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696792",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696792_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cefradine\" outputclass=\"int-drug\">cefradine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cefradine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696793",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696793_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ceftaroline\" outputclass=\"int-drug\">ceftaroline</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ceftaroline  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftaroline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696794",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696794_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ceftazidime\" outputclass=\"int-drug\">ceftazidime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ceftazidime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftazidime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696795",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696795_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ceftobiprole\" outputclass=\"int-drug\">ceftobiprole</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ceftobiprole  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftobiprole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696796",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696796_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ceftolozane\" outputclass=\"int-drug\">ceftolozane</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ceftolozane  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftolozane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696797",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696797_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ceftriaxone\" outputclass=\"int-drug\">ceftriaxone</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ceftriaxone  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftriaxone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696798",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696798_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cefuroxime\" outputclass=\"int-drug\">cefuroxime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cefuroxime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefuroxime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696799",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696799_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">Ceritinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ceritinib   is predicted to   increase   the exposure to   celecoxib .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696800",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696800_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  chlorothiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696800_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Celecoxib   increases   the risk of acute renal failure when given with   chlorothiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696801",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696801_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  chlortalidone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696801_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Celecoxib   increases   the risk of acute renal failure when given with   chlortalidone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696802",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696802_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"ciclesonide\" outputclass=\"int-drug\">ciclesonide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   ciclesonide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696803",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696803_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ciclosporin  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696803_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  ciclosporin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696804",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696804_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cidofovir\" outputclass=\"int-drug\">cidofovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cidofovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cidofovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696805",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696805_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">cilostazol</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cilostazol  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cilostazol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696806",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696806_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"ciprofloxacin\" outputclass=\"int-drug\">ciprofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   potentially   increases   the risk of seizures when given with   ciprofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciprofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696807",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696807_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  cisplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696808",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696808_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  citalopram  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696808_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  citalopram  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696809",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696809_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  clomipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696810",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696810_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">clopidogrel</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  clopidogrel  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696811",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696811_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"colistimethate\" outputclass=\"int-drug\">Colistimethate</ph> <ph outputclass=\"int-substanceQualifier\">(particularly intravenous)</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of nephrotoxicity when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Colistimethate   (particularly intravenous)   potentially   increases   the risk of nephrotoxicity when given with   celecoxib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Colistimethate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696812",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696812_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">Dabigatran</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabigatran   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696813",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696813_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">dalteparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  dalteparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696813_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">Dalteparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dalteparin   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696814",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696814_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"danaparoid\" outputclass=\"int-drug\">Danaparoid</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Danaparoid   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Danaparoid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696815",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696815_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  dapoxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696815_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  dapoxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696816",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696816_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of renal impairment when given with</ph> <ph otherprops=\"daptomycin\" outputclass=\"int-drug\">daptomycin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of renal impairment when given with   daptomycin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daptomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696817",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696817_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-drug\">darbepoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  darbepoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darbepoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696818",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696818_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  dasatinib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696819",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696819_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deferasirox\" outputclass=\"int-drug\">deferasirox</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   is predicted to   increase   the risk of gastrointestinal bleeding when given with   deferasirox .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferasirox</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696820",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696820_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696821",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696821_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"desmopressin\" outputclass=\"int-drug\">desmopressin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  desmopressin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desmopressin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696822",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696822_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">dexamethasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   dexamethasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696823",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696823_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  dipyridamole  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696824",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696824_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  dosulepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696825",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696825_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  doxepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696826",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696826_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"drospirenone\" outputclass=\"int-drug\">drospirenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  drospirenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Drospirenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696827",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696827_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  duloxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696827_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  duloxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696828",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696828_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">Edoxaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Edoxaban   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696829",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696829_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  enalapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696830",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696830_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">enoxaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  enoxaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696830_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">Enoxaparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Enoxaparin   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696831",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696831_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  eplerenone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696831_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  eplerenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696832",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696832_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"epoetin alfa\" outputclass=\"int-drug\">epoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  epoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696833",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696833_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"epoetin beta\" outputclass=\"int-drug\">epoetin beta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  epoetin beta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696834",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696834_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"epoetin zeta\" outputclass=\"int-drug\">epoetin zeta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  epoetin zeta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin zeta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696835",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696835_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  epoprostenol  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696836",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696836_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">eprosartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  eprosartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696837",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696837_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"eptifibatide\" outputclass=\"int-drug\">eptifibatide</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  eptifibatide  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eptifibatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696838",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696838_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">Erlotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal perforation when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Erlotinib   is predicted to   increase   the risk of gastrointestinal perforation when given with   celecoxib .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696839",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696839_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  escitalopram  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696839_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  escitalopram  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696840",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696840_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"flecainide\" outputclass=\"int-drug\">flecainide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   is predicted to   increase   the exposure to   flecainide .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flecainide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696841",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696841_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/celecoxib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP6415\">celecoxib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluconazole   moderately   increases   the exposure to   celecoxib .  Manufacturer advises adjust  celecoxib  dose .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696842",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696842_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">fludrocortisone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   fludrocortisone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696843",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696843_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  fluoxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696843_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  fluoxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696844",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696844_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"fluticasone\" outputclass=\"int-drug\">fluticasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   fluticasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluticasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696845",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696845_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  fluvoxamine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696845_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  fluvoxamine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696846",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696846_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fondaparinux\" outputclass=\"int-drug\">Fondaparinux</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fondaparinux   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fondaparinux</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696847",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696847_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"foscarnet\" outputclass=\"int-drug\">foscarnet</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  foscarnet  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Foscarnet</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696848",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696848_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  furosemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696849",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696849_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  gabapentin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696850",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696850_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ganciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696851",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696851_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"gentamicin\" outputclass=\"int-drug\">gentamicin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  gentamicin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gentamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696852",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696852_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"heparin (unfractionated)\" outputclass=\"int-drug\">heparin (unfractionated)</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  heparin (unfractionated)  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696852_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"heparin (unfractionated)\" outputclass=\"int-drug\">Heparin (unfractionated)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Heparin (unfractionated)   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin (unfractionated)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696853",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696853_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  hydrochlorothiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696853_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Celecoxib   increases   the risk of acute renal failure when given with   hydrochlorothiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696854",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696854_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">hydrocortisone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   hydrocortisone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696855",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696855_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  hydroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696855_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Celecoxib   increases   the risk of acute renal failure when given with   hydroflumethiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696856",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696856_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal irritation when given with</ph> <ph otherprops=\"ibandronic acid\" outputclass=\"int-drug\">ibandronic acid</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   is predicted to   increase   the risk of gastrointestinal irritation when given with   ibandronic acid .  Manufacturer advises caution and monitor side effects .    \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibandronic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696857",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696857_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ibrutinib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696858",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696858_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ifosfamide\" outputclass=\"int-drug\">ifosfamide</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ifosfamide  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ifosfamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696859",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696859_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  iloprost  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696860",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696860_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  imidapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696861",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696861_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  imipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696862",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696862_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  indapamide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696862_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Celecoxib   increases   the risk of acute renal failure when given with   indapamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696863",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696863_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  inotersen  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotersen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696864",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696864_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">irbesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  irbesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696865",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696865_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"levofloxacin\" outputclass=\"int-drug\">levofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   potentially   increases   the risk of seizures when given with   levofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696866",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696866_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  lisinopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696867",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696867_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696868",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696868_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"losartan\" outputclass=\"int-drug\">losartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  losartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696869",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696869_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  methotrexate  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696869_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of toxicity when given with</ph> <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Celecoxib   is predicted to   increase   the risk of toxicity when given with   methotrexate .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696870",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696870_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">methylprednisolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   methylprednisolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696871",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696871_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  metolazone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696871_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Celecoxib   increases   the risk of acute renal failure when given with   metolazone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696872",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696872_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"mifamurtide\" outputclass=\"int-drug\">mifamurtide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   (high-dose)   is predicted to   decrease   the efficacy of   mifamurtide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifamurtide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696873",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696873_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"mometasone\" outputclass=\"int-drug\">mometasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   mometasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696874",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696874_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   potentially   increases   the risk of seizures when given with   moxifloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696875",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696875_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"neomycin\" outputclass=\"int-drug\">neomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  neomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Neomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696876",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696876_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicorandil\" outputclass=\"int-drug\">Nicorandil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal perforation when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicorandil   is predicted to   increase   the risk of gastrointestinal perforation when given with   celecoxib .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicorandil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696877",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696877_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">Nicotinic acid</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicotinic acid   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696878",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696878_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  nortriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696879",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696879_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"ofloxacin\" outputclass=\"int-drug\">ofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   potentially   increases   the risk of seizures when given with   ofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696880",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696880_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">olmesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  olmesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696881",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696881_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"omega-3-acid ethyl esters\" outputclass=\"int-drug\">Omega-3-acid ethyl esters</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Omega-3-acid ethyl esters   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omega-3-acid ethyl esters</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696882",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696882_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  oxaliplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696883",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696883_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  paroxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696883_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  paroxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696884",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696884_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  pemetrexed  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696884_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Celecoxib   is predicted to   increase   the exposure to   pemetrexed .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696885",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696885_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"penicillamine\" outputclass=\"int-drug\">penicillamine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  penicillamine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Penicillamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696886",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696886_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  pentamidine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696887",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696887_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  perindopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696888",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696888_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenindione\" outputclass=\"int-drug\">Phenindione</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenindione   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696889",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696889_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"polymyxins\" outputclass=\"int-drug\">polymyxins</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  polymyxins  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Polymyxins</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696890",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696890_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"potassium aminobenzoate\" outputclass=\"int-drug\">potassium aminobenzoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  potassium aminobenzoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium aminobenzoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696891",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696891_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"potassium canrenoate\" outputclass=\"int-drug\">potassium canrenoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  potassium canrenoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium canrenoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696892",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696892_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"potassium chloride\" outputclass=\"int-drug\">potassium chloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  potassium chloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696893",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696893_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"prasugrel\" outputclass=\"int-drug\">prasugrel</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  prasugrel  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prasugrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696894",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696894_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">prednisolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   prednisolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696895",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696895_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"propafenone\" outputclass=\"int-drug\">propafenone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   is predicted to   increase   the exposure to   propafenone .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propafenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696896",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696896_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  quinapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696897",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696897_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ramipril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696898",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696898_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  regorafenib  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696899",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696899_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   moderately   decreases   the exposure to   celecoxib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696900",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696900_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">Rivaroxaban</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rivaroxaban   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696901",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696901_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  sertraline  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696901_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  sertraline  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696902",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696902_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of renal impairment when given with</ph> <ph otherprops=\"sodium clodronate\" outputclass=\"int-drug\">sodium clodronate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   is predicted to   increase   the risk of renal impairment when given with   sodium clodronate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium clodronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696903",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696903_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"sodium picosulfate\" outputclass=\"int-drug\">sodium picosulfate</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  sodium picosulfate  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium picosulfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696904",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696904_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  spironolactone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696904_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  spironolactone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696905",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696905_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"streptokinase\" outputclass=\"int-drug\">Streptokinase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Streptokinase   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696906",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696906_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"streptomycin\" outputclass=\"int-drug\">streptomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  streptomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696907",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696907_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"streptozocin\" outputclass=\"int-drug\">streptozocin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  streptozocin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptozocin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696908",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696908_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"sulfinpyrazone\" outputclass=\"int-drug\">sulfinpyrazone</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  sulfinpyrazone  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfinpyrazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696909",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696909_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  tacrolimus  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696909_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  tacrolimus  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696910",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696910_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"telavancin\" outputclass=\"int-drug\">telavancin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  telavancin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telavancin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696911",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696911_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">telmisartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  telmisartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696912",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696912_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenecteplase\" outputclass=\"int-drug\">Tenecteplase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenecteplase   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenecteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696913",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696913_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"tenofovir disoproxil\" outputclass=\"int-drug\">tenofovir disoproxil</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  tenofovir disoproxil  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenofovir disoproxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696914",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696914_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"ticagrelor\" outputclass=\"int-drug\">ticagrelor</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  ticagrelor  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ticagrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696915",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696915_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">tinzaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  tinzaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696915_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">Tinzaparin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696916",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696916_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"tirofiban\" outputclass=\"int-drug\">tirofiban</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  tirofiban  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tirofiban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696917",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696917_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"tobramycin\" outputclass=\"int-drug\">tobramycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  tobramycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tobramycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696918",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696918_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"tolvaptan\" outputclass=\"int-drug\">tolvaptan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  tolvaptan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolvaptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696919",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696919_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  torasemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696920",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696920_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  trandolapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696921",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696921_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  trastuzumab emtansine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696922",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696922_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">triamcinolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Celecoxib   increases   the risk of gastrointestinal bleeding when given with   triamcinolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696923",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696923_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  triamterene  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696923_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  triamterene  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696924",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696924_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  trimethoprim  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696924_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  celecoxib  and  trimethoprim  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696924_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  celecoxib  and  trimethoprim  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696925",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696925_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  trimipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696926",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696926_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"urokinase\" outputclass=\"int-drug\">Urokinase</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Urokinase   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Urokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696927",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696927_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"valaciclovir\" outputclass=\"int-drug\">valaciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  valaciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valaciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696928",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696928_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  valganciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696929",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696929_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"valsartan\" outputclass=\"int-drug\">valsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  valsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696930",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696930_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"vancomycin\" outputclass=\"int-drug\">vancomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  vancomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vancomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696931",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696931_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  venlafaxine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696932",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696932_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of bleeding.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  vortioxetine  can increase the risk of bleeding. \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696933",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696933_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"warfarin\" outputclass=\"int-drug\">Warfarin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Warfarin   is predicted to   increase   the risk of bleeding events when given with   celecoxib .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696934",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696934_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  xipamide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696934_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">Celecoxib</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Celecoxib   increases   the risk of acute renal failure when given with   xipamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696935",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696935_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">zidovudine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  zidovudine  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696935_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">Zidovudine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of haematological toxicity when given with</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Zidovudine   increases   the risk of haematological toxicity when given with   celecoxib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zidovudine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696936",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2#bnf_i1557280696936_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"celecoxib\" outputclass=\"int-heading-drug\">celecoxib</ph> and <ph otherprops=\"zoledronic acid\" outputclass=\"int-drug\">zoledronic acid</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  celecoxib  and  zoledronic acid  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zoledronic acid</title>"
					}
				}
			],
			"hasSearchLabel": " Celecoxib  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/celecoxib-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Celecoxib </title>"
			},
			"rdfs:label": "celecoxib"
		}
	]
}